Limited sensitivity of iodine-123-2-hydroxy-3-iodo-6-methoxy-N-[(1- ethyl-2-pyrrolidinyl)methyl]benzamide whole-body scintigraphy in patients with malignant melanoma: A comparison with thallium-201 imaging

European Journal of Nuclear Medicine

Volumn 26, Issue 12, 1999, Pages 1567-1571

  Brenner, Winfried ^a   Klomp, Hans Jürgen ^a   Bohuslavizki, Karl H ^b   Szonn, Britta ^a   Kampen, Willm U ^a   Henze, Eberhard ^a  

^a UNIVERSITY OF KIEL   (Germany)

^b UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

Author keywords

Iodine 123 2 hydroxy 3 iodo 6 methoxy N (1 ethyl 2 pyrrolidinyl)methyl benzamide; Malignant melanoma; Thallium 201; Whole body scintigraphy

Indexed keywords

IODINE 123; N [(1 ETHYL 2 PYRROLIDINYL)METHYL] 3 IODO 6 METHOXYSALICYLAMIDE; THALLIUM 201;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; FEMALE; HUMAN; INTERMETHOD COMPARISON; MALE; MELANOMA; POSITRON EMISSION TOMOGRAPHY; SKIN METASTASIS; WHOLE BODY SCINTISCANNING;

ADULT; AGED; BENZAMIDES; EVALUATION STUDIES; FEMALE; HUMANS; MALE; MELANOMA; MIDDLE AGED; PROSPECTIVE STUDIES; PYRROLIDINES; RADIOPHARMACEUTICALS; SENSITIVITY AND SPECIFICITY; SKIN NEOPLASMS; THALLIUM RADIOISOTOPES;

EID: 0033430933     PISSN: 03406997     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002590050496     Document Type: Article

References (23)

1. 201Tl whole-body scintigraphy in patients with malignant melanoma. Nucl Med Commun 1997; 18: 230-234.
2. 2. Rettenbacher L, Koller J, Kässmann H, Galvan G. Detection of melanoma metastases with thallium-201 scintigraphy. J Nucl Med 1998; 39: 798-802.
3. 201Tl in tumor bearing animals and inflammatory lesion induced animals. Eur J Nucl Med 1987; 12: 567-572.
4. 4. Brandau W, Kirchner B, Bartenstein P, Sciuk J, Kamanabrou D, Schober O. N-(2-diethylaminoethyl)-4-[123I]iodobenzamide as a tracer for the detection of malignant melanoma: simple synthesis, improved labelling technique and first clinical results. Eur J Nucl Med 1993; 20: 238-243.
5. 5. Michelot JM, Moreau MFC, Veyre AJ, et al. Phase II scintigraphic clinical trial of malignant melanoma and metastases with iodine-123-N-(2-diethylaminoethyl-4-iodobenzamide). J Nucl Med 1993; 34: 1260-1266.
6. 6. Maffioli L, Mascheroni L, Mongioj V, et al. Scintigraphic detection of melanoma metastases with a radiolabeled benzamide ([iodine-123]-(S)-IBZM). J Nucl Med 1994; 35: 1741-1747.
7. 7. Nicholl C, Mohammed A, Hull WE, Bubeck B, Eisenhut M. Pharmacokinetics of iodine-123-IMBA for melanoma imaging. J Nucl Med 1997; 38: 127-133.
8. 8. Larisch R, Schulte KW, Vosberg H, Ruzicka T, Müller-Gärtner HW. Differential accumulation of iodine-123-iodobenzamide in melanotic and amelanotic melanoma metastases in vivo. J Nucl Med 1998; 39: 996-1001.
9. 9. Stone CA, Goodacre TEE. Surgical management of regional lymph nodes in primary cutaneous malignant melanoma: Review. Br J Surg 1995; 82: 1015-1022.
10. 10. Rinne D, Baum RP, Hoer G, Kaufmann R. Primary staging and follow-up of high risk melanoma patients with whole-body 18F-fluorodeoxyglucose positron emission tomography: results of a prospective study of 100 patients. Cancer 1998; 82: 1664-1671.
11. 201Tl scintigraphy. Clin Nucl Med 1996; 21: 67.
12. 12. Miyazaki T, Ohnishi T, Hoshi H, et al. Tl-201 uptake in an intracranial primary malignant melanoma. Clin Nucl Med 1996; 21: 572.
13. 201Tl. Clin Nucl Med 1998; 23: 764-766.
14. 14. Steinert HC, Huch Boeni RA, Boeni R, Westera G, Buck A. Dopamine-D2 receptor scintigraphy with I-123-Iodobenzofuran in malignant melanoma. Nuklearmedizin 1995; 34: 146-150.
15. 15. Everaert H, Bossuyt A, Flamen P, Mertens J, Franken PR. Visualizing ocular melanoma using iodine-123-N-(2-diethylamoniethyl)4-iodobenzamide SPECT. J Nucl Med 1997; 38: 870-873.
16. 16. Everaert H, Flamen P, Franken PR, Verhaeghe W, Bossuyt A. Sigma-receptor imaging by means of I-123-IDAB scintigraphy: clinical application in melanoma and non-small cell lung cancer. Anticancer Res 1997; 17: 1577-1582.
17. 17. Larisch R, Klimke A. On the clinical impact of cerebral dopamine D2 receptor scintigraphy. Nuklearmedizin 1998; 37: 245-250.
18. 18. Sehweil AM, McKillop JH, Milroy R, Wilson R, Abdel-Dayem HM, Omar YT. Mechanism of Tl-201 uptake in tumours. Eur J Nucl Med 1989; 15: 376-379.
19. 19. Henker C, Bida B, Markwardt J, Schlag P. Diagnostic value of I-123-IBZM-scintigraphy for staging of malignant melanomas. Nuklearmedizin 1997; 36: 1-6.
20. 20. Hoefnagel CA, Rankin EM, Valdes Olmos RA, Israels SP, Pavel S, Janssen AGM. Sensitivity versus specificity in melanoma imaging using iodine-123 iodobenzamide and indium-111 pentetreotide. Eur J Nucl Med 1994; 21: 587-588.
21. 21. Siccardi AG, Buraggi GL, Natali PG, et al. European multicenter study on melanoma immunoscintigraphy by means of Tc-99m-labeled monoclonal antibody fragments. Eur J Nucl Med 1990; 16: 317-323.
22. 22. Blend MJ, Hyun H, Patel B, Sullivan K, Salk D. Radioimmunoscintigraphy in patients with early stage malignant melanoma. J Nucl Med 1996; 37: 252-257.
23. 23. Jackson FI, McPershon TA, Lentle BC. Gallium-67 scintigraphy in multisystem malignant melanoma. Radiology 1977; 122: 163-167.